Welcome to MYCOR GmbH, a company founded 4 years ago with the goal of early detection of amyloidosis, for which no screening method existed until then.

At MYCOR, our effort is to use the latest technology and research to diagnose patients with cardiac amyloidosis. Our Team of experts is committed to provide best possible screening strategies to our patients. We are proud to be at the forefront in that important field.

We are passionate about improving the lives of people affected by cardiac amyloidosis, and we will continue our research and development efforts to improve outcomes for patients.

Our SYGNAL algorithm is the only non-invasive and highly accurate screening method that detects cardiac amyloidosis in its early stages.

We are pleased to offer the latest and patented* technology for the detection of cardiac amyloidosis with our innovative SYGNAL algorithm.

*patent pending